Page 117 - GPD-3-3

Gene & Protein in Disease Exploring serum inflammatory biomarkers in GBM

protein in human cancer cells and is expressionally 81. Gupta D, Lis CG. Pretreatment serum albumin as a
modulated by dexamethasone, TNFalpha, and TGFbeta. predictor of cancer survival: A systematic review of the
Gene Ther. 2003;10(3):198-205. epidemiological literature. Nutr J. 2010;9:69.
doi: 10.1038/sj.gt.3301887 doi: 10.1186/1475-2891-9-69
71. Sampath P, Weaver CE, Sungarian A, Cortez S, Alderson L, 82. Radu R, Petrescu GED, Gorgan RM, Brehar FM. GFAPδ:
Stopa EG. Cerebrospinal fluid (vascular endothelial growth A promising biomarker and therapeutic target in
factor) and serologic (recoverin) tumor markers for glioblastoma. Front Oncol. 2022;12:859247.
malignant glioma. Cancer Control. 2004;11(3):174-180.
doi: 10.3389/fonc.2022.859247
doi: 10.1177/107327480401100305
83. Zottel A, Jovčevska I, Šamec N, Komel R. Cytoskeletal
72. Gao Y, Zhang E, Liu B, et al. Integrated analysis identified proteins as glioblastoma biomarkers and targets for
core signal pathways and hypoxic characteristics of human therapy: A systematic review. Crit Rev Oncol Hematol.
glioblastoma. J Cell Mol Med. 2019;23(9):6228-6237. 2021;160:103283.
doi: 10.1111/jcmm.14507 doi: 10.1016/j.critrevonc.2021.103283
73. Salmaggi A, Eoli M, Frigerio S, Ciusani E, Silvani A, 84. Uceda-Castro R, van Asperen JV, Vennin C, et al. GFAP
Boiardi A. Circulating intercellular adhesion molecule-1 splice variants fine-tune glioma cell invasion and tumour
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) dynamics by modulating migration persistence. Sci
and plasma thrombomodulin levels in glioblastoma patients. Rep. 2022;12(1):424.
Cancer Lett. 1999;146(2):169-172.
doi: 10.1038/s41598-021-04127-5
doi: 10.1016/s0304-3835(99)00255-4
85. van Asperen JV, Robe PAJT, Hol EM. GFAP alternative
74. Van Rossum GaD, Fred L. Python 3 Reference Manual. splicing and the relevance for disease - a focus on diffuse
United States: CreateSpace; 2009. gliomas. ASN Neuro. 2022;14.
75. Krämer A, Green J, Pollard J Jr., Tugendreich S. Causal doi: 10.1177/17590914221102065
analysis approaches in ingenuity pathway analysis.
Bioinformatics. 2014;30(4):523-530. 86. Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in
inflammation. Signal Transduct Target Ther. 2017;2:17023.
doi: 10.1093/bioinformatics/btt703
doi: 10.1038/sigtrans.2017.23
76. Güven E, Afzal M, Kazmi I. Screening the significant hub
genes by comparing tumor cells, normoxic and hypoxic 87. Carenza C, Franzese S, Castagna A, et al. Perioperative
glioblastoma stem-like cell lines using co-expression corticosteroid treatment impairs tumor-infiltrating
dendritic cells in patients with newly diagnosed adult-type
analysis in glioblastoma. Genes (Basel). 2022;13(3):518.
diffuse gliomas. Front Immunol. 2023;13:1074762.
doi: 10.3390/genes13030518
doi: 10.3389/fimmu.2022.1074762
77. Plotly Technologies Inc. Collaborative Data Science.
Montréal, QC: Plotly Technologies Inc.; 2015. 88. Lamano JB, Lamano JB, Li YD, et al. Glioblastoma-derived
IL6 induces immunosuppressive peripheral myeloid cell
78. Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: PD-L1 and promotes tumor growth. Clin Cancer Res.
Protein-protein association networks with increased 2019;25(12):3643-3657.
coverage, supporting functional discovery in genome-
wide experimental datasets. Nucleic Acids Res. doi: 10.1158/1078-0432.Ccr-18-2402
2019;47(D1):D607-D613. 89. Pitter KL, Tamagno I, Alikhanyan K, et al. Corticosteroids
compromise survival in glioblastoma. Brain. 2016;139(Pt
doi: 10.1093/nar/gky1131
5):1458-1471.
79. Edimiris-Herrmann A, Kolberg-Liedtke C, Bittner AK, et al.
The role of C-reactive protein as a prognostic biomarker in doi: 10.1093/brain/aww046
patients with early breast cancer treated with neoadjuvant 90. West AJ, Tsui V, Stylli SS, et al. The role of interleukin-
chemotherapy. Breast Care (Basel). 2022;17(4):371-376. 6-STAT3 signalling in glioblastoma. Oncol Lett.
2018;16(4):4095-4104.
doi: 10.1159/000522606
doi: 10.3892/ol.2018.9227
80. Mantzorou M, Koutelidakis A, Theocharis S, Giaginis C.
Clinical value of nutritional status in cancer: What is its 91. Nakamura T, Asanuma K, Hagi T, Sudo A. Creactive protein
impact and how it affects disease progression and prognosis? and related predictors in soft tissue sarcoma (Review). Mol
Nutr Cancer. 2017;69(8):1151-1176. Clin Oncol. 2024;20(1):6.
doi: 10.1080/01635581.2017.1367947 doi: 10.3892/mco.2023.2704

Volume 3 Issue 3 (2024) 17 doi: 10.36922/gpd.3580